A comparison of drug-relevant genetic raw data from direct-to-consumer genetic test providers and evaluation services with conventional laboratory tests

A comparison of pharmacogenomic raw genotyping data from direct-to-consumer genetic testing services and third-party interpretation websites with conventional laboratory testing

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

ISRCTN

Registry ID

ISRCTN24498451

Enrollment

Registered

2023-08-10

Start date

2023-09-01

Completion date

Unknown

Last updated

2023-10-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Descriptive analysis of pharmacogenomic results of from DTC-GT services and third-party interpretation websites compared to conventional laboratory testing Not Applicable

Interventions

Comparison of pharmacogenomic results of from DTC-GT services and third-party interpretation websites with conventional laboratory testing regarding CYP2D6, CYP2C19, CYP2C9 and UGT1A1

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Signed informed consent 2. Ability to understand and follow study procedures and understand informed consent 3. Age 18-75 years

Exclusion criteria

Exclusion criteria: 1. People at higher risk for infection: age over 75 years, people taking immunosuppressive drugs or with immunodeficiencies 2. People at higher risk for blood loss: people taking anticoagulation and or antiplatelet drugs, people with coagulation disorders

Design outcomes

Primary

Measure	Time frame
Gain an insight into the quality of personal PGx information freely accessible by patients via DTC-GT, based on the raw genotyping data provided by DTC-GT, the evaluated raw genotyping data by TPI services and by comparison to results obtained through conventional laboratory testing. Completeness and correctness of the results will be assessed descriptively for each PGx enzyme tested (CYP2D6, CYP2C19, CYP2C9 and UGT1A1).	—

Measure

Time frame

Gain an insight into the quality of personal PGx information freely accessible by patients via DTC-GT, based on the raw genotyping data provided by DTC-GT, the evaluated raw genotyping data by TPI services and by comparison to results obtained through conventional laboratory testing. Completeness and correctness of the results will be assessed descriptively for each PGx enzyme tested (CYP2D6, CYP2C19, CYP2C9 and UGT1A1).

—

Secondary

Measure	Time frame
There are no secondary outcome measures	—

Countries

Switzerland

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026